- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04377048
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
May 4, 2020 updated by: National Taiwan University Hospital
Nivolumab as add-on to Gemcitabine/S-1 in Metastatic Pancreatic Cancer: a Phase II Trial
This study assumes that to achieve significant therapeutic efficacy in advanced pancreatic cancer with immunotherapy, the immune system must remain relatively intact.
Therefore, early use, low tumor load, adequate organ function, and slow growth of the tumor are the key points.
Stage IV pancreatic adenocarcinoma patients with limited metastatic lesions and adequate organ function will be enrolled.
Gemcitabine plus S-1 (GS) will be administered initially, and then CA 19-9 will be evaluated.
Those fulfilling pre-defined criteria of CA 19-9 will receive nivolumab add-on therapy.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
38
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- histologically proven pancreatic adenocarcinoma
- newly diagnosed, stage IV pancreatic cancer with limited metastases and tumor burden
- no previous radiotherapy, chemotherapy, targeted therapy, curative surgery, local therapy (eg. radiofrequency ablation, irreversible electroporation, etc.), immunotherapy, cell therapy (autologous or allogenic) used for pancreatic cancer
- presence of at least one measurable lesion at the pancreas and at least one measurable metastatic lesion
- age between 20 and 75 years at registration
- ECOG performance status of 0 or 1
- adequate major organ functions
- baseline CA 19-9 > upper limit of normal
- Glasgow prognostic score of 0 (ie. albumin ≥ 3.5 g/dL and CRP ≤ 1 mg/dL)
- ability to take study medication (S-1) orally
- no clinically significant abnormal ECG findings within 28 days prior to registration
- Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons) must agree to use contraception from the time of informed consent until 5 months or more after the last dose of investigational products. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product.
- Men must agree to use contraception from the start of study treatment until 7 months or more after the last dose of the investigational product.
- Sign written informed consent
Exclusion Criteria:
- interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity within 28 days prior to registration
- presence of diarrhea ≥ CTCAE v.5.0 grade 2
- concomitant systemic infection requiring treatment
- clinically significant co-morbid medical conditions, including cardiovascular disease known autoimmune disease
- concurrent autoimmune disease or history of chronic or recurrent autoimmune disease
- prior organ allograft or allogeneic bone marrow transplantation
- received systemic corticosteroids (except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before registration
- HBV (positive HBsAg or HBV DNA) or HCV carrier (positive anti-HCV or HCV RNA)
- known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome
- moderate or severe ascites, pleural effusion, or pericardial effusion requiring treatment
- central nervous system metastasis
- prior or concurrent malignancies within the last 3 years, with the exception of carcinoma in situ of the cervix, or basal type skin cancer
- concomitant treatment with flucytosine, phenytoin or warfarin
- any major surgery within 4 weeks of study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.
- transfusion from 72 hours prior to registration to the first dose of study drug administration
- pregnant women or nursing mothers, or positive pregnancy tests
- severe mental disorder
- treatment with botanical preparations (eg, herbal supplements or traditional Chinese medicines) intended for general health support or to treat the disease under study within 2 weeks prior to registration
- vaccine therapies for prevention of infectious diseases within 4 weeks of study drug administration except inactivated seasonal influenza vaccine
- any condition requiring anti-platelet or anticoagulant therapy within 12 weeks prior to registration
- oral or iv antibiotic use within 2 weeks prior to registration
- uncontrollable pain caused by a tumor
- receiving antineoplastic agents within 28 days before registration
- patients judged by the principal investigator or subinvestigators to be inappropriate as subjects of this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Nivolumab/GS
Part-1: GS Induction
Part-2: Nivolumab Add-On
The treatment will be continued until disease progression, intolerance to study treatment or death. |
as described in "NGS Arm"
as described in "NGS Arm"
as described in "NGS Arm"
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
response rate
Time Frame: 6 weeks
|
overall response rate of gemcitabine/S-1/nivolumab
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shih-Hung Yang, M.D., Ph.D., Department of Oncology, National Taiwan University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1.
- Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schutz E, Khemka V. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018 Feb;36(1):96-102. doi: 10.1007/s10637-017-0525-1. Epub 2017 Nov 8. Erratum In: Invest New Drugs. 2019 Aug;37(4):797.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
July 1, 2020
Primary Completion (ANTICIPATED)
July 1, 2022
Study Completion (ANTICIPATED)
December 31, 2022
Study Registration Dates
First Submitted
May 4, 2020
First Submitted That Met QC Criteria
May 4, 2020
First Posted (ACTUAL)
May 6, 2020
Study Record Updates
Last Update Posted (ACTUAL)
May 6, 2020
Last Update Submitted That Met QC Criteria
May 4, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Gemcitabine
- Nivolumab
- Tegafur
Other Study ID Numbers
- 202001045MIPA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IV Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Panbela Therapeutics, Inc.CompletedPancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Stage IV Pancreatic CancerUnited States, Australia
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...United States
-
University of ChicagoNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Malignant Gastrointestinal Neoplasm | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Gallbladder Carcinoma | Stage IV Gallbladder Cancer | Stage IV Gastric Cancer | Stage IIIA Gallbladder Cancer | Stage... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); National Institute of Nursing Research (NINR)CompletedStage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic CancerUnited States
-
Jerome Canady, M.D.Active, not recruitingStage IV Lung Cancer | Stage IV Bladder Cancer | Stage IV Pancreatic Cancer | Recurrent Malignant Solid Neoplasm | Stage IV Breast Cancer | Stage IV Renal Cell Cancer | Stage IV Prostate Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Stage IV Non-small Cell Lung Cancer | Stage... and other conditionsUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Emory UniversityIpsen; Taiho Oncology, Inc.RecruitingGastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditionsUnited States
-
Seoul National University HospitalNational Cancer Center, Korea; Chonbuk National University Hospital; Asan Medical... and other collaboratorsCompletedStage IV Lung Cancer | Stage IV Pancreatic Cancer | Stage IV Breast Cancer | Pediatric Brain Tumor | Stage IV Colon Cancer | Stage IV Gastric Cancer | Stage IV Liver Cancer | Malignant Hematologic Neoplasm | Pediatric Solid Tumor | Pediatric Lymphoma | Biliary Cancer Metastatic | Pediatric LeukemiaKorea, Republic of
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingPancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8United States
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan
-
IRCCS San RaffaeleBristol-Myers SquibbRecruiting